Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimization of Subsecond Estradiol Detection through Analysis of Surface-Analyte Interactions.

ACS electrochemistry·2026
Same author

The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.

The oncologist·2026
Same author

Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Prospective Multisite Validation and Comparison with MRI.

The Journal of urology·2026
Same author

Guanosine contributes to rapid purinergic regulation of dopamine during ischemia.

Purinergic signalling·2026
Same author

Comparative Performance of Prostate Cancer Risk Prediction Tools in Gay, Bisexual, and Other Men Who Have Sex With Men vs Heterosexual Men.

Urology·2026
Same author

Clinical and Reader Associated Correlates of Clinically Significant Magnetic Resonance Imaging-Invisible Prostate Cancer Based on Negative Scans.

The Journal of urology·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K

Multigene Testing in Localized Prostate Cancer.

Ashley E Ross1

  • 1Presented by Ashley E. Ross, MD, PhD, Departments of Urology, Oncology, and Pathology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins School of Medicine, Baltimore, Maryland.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 27, 2016
PubMed
Summary
This summary is machine-generated.

Multigene tests aid prostate cancer risk stratification but require prospective validation. Molecular tests may offer additional value in specific clinical scenarios, according to updated guidelines.

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.4K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.9K

Related Experiment Videos

Last Updated: Mar 20, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.4K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.9K

Area of Science:

  • Oncology
  • Genetics
  • Clinical Trials

Background:

  • Commercially available multigene tests are used for prostate cancer risk stratification.
  • Current validation for these tests is primarily retrospective.
  • Prospective studies are essential to confirm their clinical utility.

Purpose of the Study:

  • To evaluate the role of multigene and molecular tests in prostate cancer management.
  • To assess the need for prospective validation of existing risk stratification tools.
  • To understand the circumstances where molecular tests provide added clinical value.

Main Methods:

  • Review of existing literature on multigene tests for prostate cancer.
  • Analysis of retrospective validation data.
  • Consideration of updated clinical guidelines (NCCN).

Main Results:

  • Multigene tests are available but lack prospective clinical validation.
  • Molecular tests can provide valuable information in specific contexts.
  • NCCN Guidelines suggest considering molecular tests for specific prognostic assessments.

Conclusions:

  • Prospective studies are crucial for establishing the definitive clinical role of multigene tests in prostate cancer.
  • Molecular testing offers supplementary prognostic information, guiding treatment decisions in select cases.
  • Updated guidelines acknowledge the potential benefit of molecular tests for predicting outcomes like metastasis or progression.